Clostridioides difficile Infection as a Predictor of Chemotherapy-Related Adverse Outcomes in Colon Cancer (ACG 2026) - Aug 29, 2026 - Abstract #P1306; Pres time: Oct 11, 2026; 03:30 PM - 07:00 PM; Location: Exhibit Halls A - D (Level 3); "Introduction: Chemotherapy-induced diarrhea affects 50-80% of colon cancer patients on fluorouracil/irinotecan regimens, causing dose reductions, treatment discontinuation, AKI, sepsis, and mortality...Cases had CDI (ICD-10 code: A04.7) within 90 days of the index date, confirmed by oral vancomycin or fidaxomicin prescription... After propensity score matching, 1,492 CDI and 1,492 non-CDI patients were included. Median age was 66 years (IQR 17); 47.3% were female. The CDI cohort had significantly higher rates of diarrhea at 14 days (HR 4.455; 95% CI, 2.996â6.625) and 30 days (HR 4.560; 95% CI, 3.383â6.146), chemotherapy-induced colitis (HR 3.702; 95% CI, 2.455â5.582), AKI within 30 days (HR 1.733; 95% CI, 1.405â2.137), sepsis within 30 days (HR 5.187; 95% CI, 2.951â9.117), neutropenia within 30 days (HR 2.178; 95% CI, 1.439â3.298), recurrent CDI days 30â180 (HR 37.181; 95% CI, 22.599â61.173), and..."
Adverse events • Colon Cancer • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Mucositis • Neutropenia • Oncology • Septic Shock • Solid Tumor
|
|
Devvrat Yadav MD 1; Haritha Gandicheruvu MD 2; Chiranjeevi Sainatham MD 3; Gizem Kaya MD 4; Rishi Chowdhary MBBS 5; Ruchita Ruturaj Jadhav MD MPH 2
|